Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
Outlook Therapeutics, a biopharmaceutical company, appointed Kevin Lundquist as CFO to lead the financial and operational infrastructure as it prepares for the U.S. commercial launch of its FDA-approved drug LYTENAVA™ for wet age-related macular degeneration. Lundquist brings over 20 years of experience in pharmaceutical finance and commercial oper…